216 related articles for article (PubMed ID: 17110452)
1. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status.
Carobbio A; Finazzi G; Guerini V; Spinelli O; Delaini F; Marchioli R; Borrelli G; Rambaldi A; Barbui T
Blood; 2007 Mar; 109(6):2310-3. PubMed ID: 17110452
[TBL] [Abstract][Full Text] [Related]
2. Leukocytosis is linked to thrombosis at diagnosis, while JAK2 V617F mutation is associated with thrombosis during the course of essential thrombocythemia.
Ohyashiki K; Kiguchi T; Ito Y; Fujimoto H; Gotoh A; Tauchi T; Miyazawa K; Kimura Y; Ohyashiki JH
Int J Hematol; 2008 May; 87(4):446-448. PubMed ID: 18409076
[No Abstract] [Full Text] [Related]
3. Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms.
Caramazza D; Caracciolo C; Barone R; Malato A; Saccullo G; Cigna V; Berretta S; Schinocca L; Quintini G; Abbadessa V; Di Raimondo F; Siragusa S
Ann Hematol; 2009 Oct; 88(10):967-71. PubMed ID: 19214510
[TBL] [Abstract][Full Text] [Related]
4. Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients.
Patriarca A; Pompetti F; Malizia R; Iuliani O; Di Marzio I; Spadano A; Dragani A
Blood Transfus; 2010 Jan; 8(1):21-7. PubMed ID: 20104275
[TBL] [Abstract][Full Text] [Related]
5. Leukocytosis and risk stratification assessment in essential thrombocythemia.
Carobbio A; Antonioli E; Guglielmelli P; Vannucchi AM; Delaini F; Guerini V; Finazzi G; Rambaldi A; Barbui T
J Clin Oncol; 2008 Jun; 26(16):2732-6. PubMed ID: 18443353
[TBL] [Abstract][Full Text] [Related]
6. The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia.
Hsiao HH; Yang MY; Liu YC; Lee CP; Yang WC; Liu TC; Chang CS; Lin SF
Exp Hematol; 2007 Nov; 35(11):1704-7. PubMed ID: 17920754
[TBL] [Abstract][Full Text] [Related]
7. Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Cacciola E; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Leone G; Barbui T;
Ann Hematol; 2010 Feb; 89(2):141-6. PubMed ID: 19582452
[TBL] [Abstract][Full Text] [Related]
8. Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia.
De Stefano V; Za T; Rossi E; Fiorini A; Ciminello A; Luzzi C; Chiusolo P; Sica S; Leone G
Haematologica; 2009 May; 94(5):733-7. PubMed ID: 19336736
[TBL] [Abstract][Full Text] [Related]
9. Impact of JAK2V617F mutation on thrombosis and myeloid transformation in essential thrombocythemia: a multivariate analysis by Cox regression in 141 patients.
Chim CS; Sim JP; Chan CC; Kho BC; Chan JC; Wong LG; Law M; Liang R; Kwong YL
Hematology; 2010 Aug; 15(4):187-92. PubMed ID: 20670476
[TBL] [Abstract][Full Text] [Related]
10. Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain.
Ziakas PD
Haematologica; 2008 Sep; 93(9):1412-4. PubMed ID: 18641024
[No Abstract] [Full Text] [Related]
11. Plasma levels of angiogenic factors and circulating endothelial cells in essential thrombocythemia: correlation with cytoreductive therapy and JAK2-V617F mutational status.
Treliński J; Wierzbowska A; Krawczyńska A; Sakowicz A; Pietrucha T; Smolewski P; Robak T; Chojnowski K
Leuk Lymphoma; 2010 Sep; 51(9):1727-33. PubMed ID: 20615083
[TBL] [Abstract][Full Text] [Related]
12. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.
Alvarez-Larrán A; Pereira A; Guglielmelli P; Hernández-Boluda JC; Arellano-Rodrigo E; Ferrer-Marín F; Samah A; Griesshammer M; Kerguelen A; Andreasson B; Burgaleta C; Schwarz J; García-Gutiérrez V; Ayala R; Barba P; Gómez-Casares MT; Paoli C; Drexler B; Zweegman S; McMullin MF; Samuelsson J; Harrison C; Cervantes F; Vannucchi AM; Besses C
Haematologica; 2016 Aug; 101(8):926-31. PubMed ID: 27175028
[TBL] [Abstract][Full Text] [Related]
13. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia.
Carobbio A; Finazzi G; Antonioli E; Guglielmelli P; Vannucchi AM; Delaini F; Guerini V; Ruggeri M; Rodeghiero F; Rambaldi A; Barbui T
Blood; 2008 Oct; 112(8):3135-7. PubMed ID: 18587010
[TBL] [Abstract][Full Text] [Related]
14. JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients.
Palandri F; Ottaviani E; Salmi F; Catani L; Polverelli N; Fiacchini M; Martinelli G; Baccarani M; Vianelli N
Leuk Lymphoma; 2009 Feb; 50(2):247-53. PubMed ID: 19235016
[TBL] [Abstract][Full Text] [Related]
15. Extrinsic blood coagulation pathway and risk factors for thrombotic events in patients with essential thrombocythemia.
Stankowska K; Gadomska G; Boinska J; Michalska M; Bartoszewska-Kubiak A; Rość D
Pol Arch Med Wewn; 2016 May; 126(5):340-6. PubMed ID: 27243342
[TBL] [Abstract][Full Text] [Related]
16. Prognostic utility of spontaneous erythroid colony formation and JAK2 mutational analysis for thrombotic events in essential thrombocythaemia.
Weston H; Cowell V; Grimmett K; Saal R; Jones M; Mills T; Gill D; Marlton P; Bird R; Mollee P
Intern Med J; 2011 May; 41(5):408-15. PubMed ID: 20681956
[TBL] [Abstract][Full Text] [Related]
17. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera.
Gangat N; Wolanskyj AP; Schwager SM; Hanson CA; Tefferi A
Cancer; 2009 Dec; 115(24):5740-5. PubMed ID: 19806641
[TBL] [Abstract][Full Text] [Related]
18. Leukocytosis, JAK2V617F mutation, and hemostasis in myeloproliferative disorders.
Marchetti M; Falanga A
Pathophysiol Haemost Thromb; 2008; 36(3-4):148-59. PubMed ID: 19176988
[TBL] [Abstract][Full Text] [Related]
19. Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study.
Palandri F; Polverelli N; Catani L; Ottaviani E; Baccarani M; Vianelli N
Ann Hematol; 2011 Aug; 90(8):933-8. PubMed ID: 21287350
[TBL] [Abstract][Full Text] [Related]
20. Thrombosis in primary myelofibrosis: incidence and risk factors.
Barbui T; Carobbio A; Cervantes F; Vannucchi AM; Guglielmelli P; Antonioli E; Alvarez-Larrán A; Rambaldi A; Finazzi G; Barosi G
Blood; 2010 Jan; 115(4):778-82. PubMed ID: 19965680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
